| 9.1 All parallel‐group trials and first‐period cross‐over trials |
7 |
792 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.62 [‐0.91, ‐0.33] |
| 9.1.1 High risk of bias |
7 |
792 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.62 [‐0.91, ‐0.33] |
| 9.2 Subgroup analysis: types of scales |
7 |
792 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.62 [‐0.91, ‐0.33] |
| 9.2.1 Conners' Global Index ‐ Teacher (CGI‐T) |
1 |
314 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.91 [‐1.14, ‐0.68] |
| 9.2.2 Groninger Behaviour Observation Scale (GBOS) |
1 |
43 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.84 [‐1.46, ‐0.21] |
| 9.2.3 Conners' Teacher Rating Scale (CTRS‐RS) |
1 |
75 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.08 [‐0.54, 0.37] |
| 9.2.4 Conners' Teacher Rating Scale ‐ Oppositional behaviour (CRS‐R) |
1 |
49 |
Std. Mean Difference (IV, Random, 95% CI) |
0.06 [‐0.50, 0.62] |
| 9.2.5 Conners' Teacher Rating Scale ‐ Conduct problems |
1 |
25 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.67 [‐1.48, 0.14] |
| 9.2.6 IOWA Conners' Rating Scale ‐ Oppositional/Defiant (IOWA‐O/D) |
2 |
286 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.86 [‐1.12, ‐0.59] |
| 9.3 Subgroup analysis: dose |
7 |
820 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.61 [‐0.88, ‐0.34] |
| 9.3.1 Low dose |
2 |
71 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.67 [‐1.16, ‐0.19] |
| 9.3.2 High dose |
4 |
541 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.66 [‐1.05, ‐0.27] |
| 9.3.3 Unknown dose |
2 |
208 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.41 [‐1.29, 0.46] |
| 9.4 Subgroup analysis: duration of treatment |
7 |
792 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.62 [‐0.91, ‐0.33] |
| 9.4.1 Short term (up to 6 months) |
7 |
792 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.62 [‐0.91, ‐0.33] |
| 9.5 Subgroup analysis: parallel‐group trials versus first‐period cross‐over trials |
7 |
792 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.62 [‐0.91, ‐0.33] |
| 9.5.1 Parallel‐group trials |
7 |
792 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.62 [‐0.91, ‐0.33] |
| 9.6 Cross‐over trials (endpoint data) |
16 |
1302 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.75 [‐0.87, ‐0.63] |
| 9.6.1 High risk of bias |
16 |
1302 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.75 [‐0.87, ‐0.63] |
| 9.7 Subgroup analysis: cross‐over trials (endpoint data): dose |
16 |
2008 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.69 [‐0.78, ‐0.60] |
| 9.7.1 Low dose |
13 |
1104 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.60 [‐0.72, ‐0.48] |
| 9.7.2 High dose |
12 |
904 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.82 [‐0.95, ‐0.68] |
| 9.8 Subgroup analysis: all parallel‐group trials and first‐period cross‐over trials (teacher‐rated) versus cross‐over trials (endpoint data) |
23 |
2094 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.72 [‐0.84, ‐0.60] |
| 9.8.1 All parallel‐group trials and first‐period cross‐over trials |
7 |
792 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.62 [‐0.91, ‐0.33] |
| 9.8.2 Cross‐over trials (endpoint data) |
16 |
1302 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.75 [‐0.87, ‐0.63] |
| 9.9 Subgroup analysis: all parallel‐group trials and cross‐over trials: vested interest |
23 |
2094 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.72 [‐0.84, ‐0.60] |
| 9.9.1 Low risk of vested interest |
6 |
509 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.67 [‐0.90, ‐0.43] |
| 9.9.2 High risk of vested interest |
17 |
1585 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.74 [‐0.89, ‐0.60] |
